One clinical trial randomized participants with pulmonary tuberculosis to customized dosing of isoniazid, based on NAT-2 activity (lower dose for slow acetylators, standard dose for intermediate acetylators, higher dose for rapid acetylators) vs. the standard dose and found fewer transaminase elevations with customized isoniazid dosing [35]. The gene discussed is NAT2; the disease is pulmonary tuberculosis.